Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SOL S.p.A. (SOL.MI)
Monza, MI, IT
SOL S.p.A., a global enterprise established in Monza, Italy, in 1927, operates as a subsidiary of Gas and Technologies World BV. The company primarily focuses on the research, manufacturing, and distribution of a diverse array of technical and medical gases, while simultaneously delivering comprehensive home healthcare solutions and associated medical equipment. Its extensive gas portfolio includes vital elements such as oxygen, nitrogen, and argon, alongside specialized gas mixtures, high-purity gases for the electronics industry, and food-grade gases. These products are supplied to various sectors including chemical, electronics, steel, metal, and food processing, as well as supporting environmental protection, scientific research, and healthcare. In the realm of home healthcare, SOL provides critical in-home therapies like oxygen, mechanical ventilation, and aerosol treatments. It also specializes in the diagnosis and management of respiratory sleep disorders, offers artificial nutrition programs, insulin pump therapy, immunotherapy, and dedicated support for pain and Parkinson's disease. Further extending its healthcare reach, the company delivers general home health and social care services, augmented by telemedicine platforms, digital health tools, and a range of healthcare aids. Beyond these core gas and home healthcare operations, SOL S.p.A. engages in a variety of complementary ventures. These encompass the design, construction, and management of biobanks; the generation and sale of hydroelectric power; and the provision of pre- and post-natal diagnostic screening. The company also develops and markets diagnostic systems and products for research and clinical applications across hospital, environmental, veterinary, and food sectors, alongside specialized bioshipping services for the secure transfer, storage, and handling of biological samples. Additional services include professional training, electromedical equipment support, hospital hygiene, environmental monitoring, and ambulance management, all facilitated by its proprietary InfoHealth SOLution web platform for operational oversight.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.40% | -2.59% | -1.91% | +9.50% | +13.34% | +17.59% | +24.59% | +120.27% | +240.77% | +592.40% | +1,473.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%+10.3% ★ Q4'25: +20.0% (vs Q4'23)
-
EPS growth Chemicals: +11.7%+12.9% ★ Q4'25: +26.0% (vs Q4'23)
-
FCF margin FCF growth · Chemicals: +41.7%+5.0% Q4'25: +4.9% (vs Q4'23)
-
EBIT margin Chemicals: +7.1%+15.2% ★ Q4'25: +12.9% (vs Q4'23)
-
ROIC Chemicals: +3.4%+11.5% ★ Q4'25: +19.8% (vs Q4'23)
-
Share dilution Chemicals: +0.0%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×1.94× Q4'25: 1.04× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
674.22M
est: 679.07M (-0.7%)
|
703.37M
est: 721.15M (-2.5%)
|
756.81M
est: 756.12M (+0.1%)
|
833.51M
est: 825.10M (+1.0%)
|
904.31M
est: 881.80M (+2.6%)
|
973.83M
est: 937.30M (+3.9%)
|
1.11B
est: 1.06B (+4.8%)
|
1.38B
est: 1.34B (+2.7%)
|
1.49B
est: 1.55B (-4.0%)
|
1.61B
est: 1.60B (+0.7%)
|
1.78B
est: 1.77B (+0.1%)
|
1.92B
1.92B – 1.93B
+8.4% YoY
|
2.06B
2.03B – 2.09B
+7.0% YoY
|
2.20B
2.20B – 2.20B
+6.8% YoY
|
| EBITDA |
146.63M
est: 164.57M (-10.9%)
|
162.36M
est: 174.76M (-7.1%)
|
162.20M
est: 183.24M (-11.5%)
|
179.22M
est: 199.96M (-10.4%)
|
194.00M
est: 213.70M (-9.2%)
|
250.82M
est: 227.15M (+10.4%)
|
255.41M
est: 257.32M (-0.7%)
|
319.04M
est: 325.47M (-2.0%)
|
372.51M
est: 419.72M (-11.2%)
|
391.08M
est: 433.08M (-9.7%)
|
439.84M
est: 480.58M (-8.5%)
|
520.93M
519.45M – 522.12M
+8.4% YoY
|
557.49M
551.09M – 565.49M
+7.0% YoY
|
595.51M
595.16M – 595.85M
+6.8% YoY
|
| EBIT |
66.50M
est: 95.41M (-30.3%)
|
79.12M
est: 101.33M (-21.9%)
|
75.62M
est: 106.24M (-28.8%)
|
89.65M
est: 115.93M (-22.7%)
|
88.53M
est: 123.90M (-28.5%)
|
139.83M
est: 131.70M (+6.2%)
|
136.12M
est: 149.19M (-8.8%)
|
190.09M
est: 188.70M (+0.7%)
|
227.90M
est: 285.86M (-20.3%)
|
234.60M
est: 294.96M (-20.5%)
|
270.03M
est: 327.31M (-17.5%)
|
354.79M
353.78M – 355.60M
+8.4% YoY
|
379.69M
375.33M – 385.14M
+7.0% YoY
|
405.58M
405.35M – 405.82M
+6.8% YoY
|
| Net Income |
32.44M
est: 37.05M (-12.4%)
|
44.13M
est: 38.81M (+13.7%)
|
40.24M
est: 52.11M (-22.8%)
|
51.88M
est: 50.79M (+2.1%)
|
49.34M
est: 53.79M (-8.3%)
|
103.05M
est: 63.85M (+61.4%)
|
89.55M
est: 87.80M (+2.0%)
|
133.69M
est: 122.45M (+9.2%)
|
145.73M
est: 141.04M (+3.3%)
|
147.70M
est: 151.60M (-2.6%)
|
166.99M
est: 166.99M (+0.0%)
|
201.00M
169.22M – 203.14M
+20.4% YoY
|
217.00M
182.70M – 219.94M
+8.0% YoY
|
241.00M
196.17M – 244.57M
+11.1% YoY
|
| SGA |
34.72M
est: 10.91M (+218.3%)
|
32.91M
est: 11.58M (+184.1%)
|
5.53M
est: 12.14M (-54.5%)
|
39.77M
est: 13.25M (+200.1%)
|
30.22M
est: 14.16M (+113.4%)
|
28.48M
est: 15.06M (+89.2%)
|
29.64M
est: 17.05M (+73.8%)
|
33.70M
est: 21.57M (+56.2%)
|
—
est: 23.69M (-100.0%)
|
—
est: 24.44M (-100.0%)
|
45.05M
est: 27.12M (+66.1%)
|
29.40M
29.31M – 29.47M
+8.4% YoY
|
31.46M
31.10M – 31.91M
+7.0% YoY
|
33.61M
33.59M – 33.63M
+6.8% YoY
|
| EPS |
0.36
est: 0.41 (-11.9%)
|
0.49
est: 0.43 (+14.5%)
|
0.44
est: 0.57 (-23.4%)
|
0.57
est: 0.56 (+1.8%)
|
0.54
est: 0.59 (-8.9%)
|
1.14
est: 0.70 (+61.9%)
|
0.99
est: 0.97 (+2.3%)
|
1.47
est: 1.35 (+8.9%)
|
1.61
est: 1.56 (+3.5%)
|
1.63
est: 1.67 (-2.4%)
|
1.84
est: 1.82 (+1.0%)
|
2.08
1.87 – 2.24
+14.3% YoY
|
2.24
2.01 – 2.42
+7.5% YoY
|
2.43
2.16 – 2.70
+8.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Giovanni Annoni | Director of Information Systems Organisation & Director | 578.2K | male |
| Marco Annoni | Deputy Chairman, Co-CEO & MD | 578.0K | male |
| Aldo Fumagalli Romario | Chairman, Co-CEO & MD | 577.5K | — |
| Giulio Fumagalli Romario | Director of Legal & Corporate Affairs and Director | 573.6K | male |
| Claudio Garbellini | General Director | — | — |
| Daniele Forni | General Director | — | — |
| Marco Filippi | Chief Financial Officer & Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SOL.MI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
